A key aide to HHS Secretary Robert F. Kennedy Jr. said that popular GLP-1 weight loss drugs -- Novo Nordisk's (NVO) Wegovy ...

Eli Lilly and Company ( NYSE: LLY) BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ET Lucas Montarce - CFO Mike Czapar - SVP, IR ...

Eli Lilly and Company (NYSE:LLY) is a leading medicine company which discovers, develops, manufactures, and markets products ...

Lilly sues four telehealth firms for unauthorized compounding of Mounjaro and Zepbound. 2. GLP 1 drugs remain in high demand ...

While the early week buzz centered around the U.S.-China trade agreement, another critical development unfolded quietly but ...

Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...

Weight loss drugs like semaglutide could add £4.5 billion to the UK economy annually, boosting productivity and reducing ...

In this article, we will take a look at the 12 Major Stocks to Buy According to Billionaires. The U.S. stock market had one of the worst starts, at least the worst start to a presidency since 1928.

When weight loss is equal, though, the GLP-1s seem to provide larger benefits. Researchers say prospective studies are needed ...

Eli Lilly is pumping iron in the GLP-1 prescription ring, gaining muscle with a 52.4% market share and a beefy $1,100 target.

Under the terms of the agreement, Septerna is eligible to receive around $2.2 billion from Novo Nordisk, including more than $200 million in upfront and near-term milestone payments.

COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral ...